drugset / Trial / NCT02405221
Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer
Phase 1
Completed
15 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collabPapiVax Biotech, Inc. · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
This study will be looking at what dose of the TA-CIN vaccine is safe and effective in patients with a history of HPV16-associated cervical cancer.
Timeline
- Start
- 2019-04-04
- Primary completion
- 2024-12-31
- Completion
- 2025-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TA-CIN | Vaccine | 100 ug | Intramuscular |